Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Acute Myeloid Leukemias

In brief

The purpose of this study is to assess if adding revumenib to standard chemotherapy improves outcomes in participants with AML with certain genetic mutations compared to chemotherapy alone. The study will also assess the safety of adding revumenib to chemotherapy.

Key facts

Study ID
NCT07211958
Run by
Syndax Pharmaceuticals
People needed
468
Starts
2025-11-25
Expected to finish
2031-01-01
Last updated by the study team
2026-07-23

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.